Abstract: Lymphoma is one of the most common malignancies in domestic cats. The lymphomagenic potential of *Felis catus* gammaherpesvirus 1 (FcaGHV1), a common infection in domestic cats, is unknown. In other species, including humans, cellular transformation by gammaherpesviruses is typically mediated by viral genes expressed during latency. We analysed tumour RNA, from diffuse large B-cell lymphomas (DLBCL) appearing in cats coinfected with FcaGHV1 and feline immunodeficiency virus (FIV) (*n* = 10), by high throughput transcriptome sequencing and reverse transcription PCR. A limited repertoire of FcaGHV transcripts was identified in five tumors, including homologs of oncogenic latency-associated transcripts, latency-associated nuclear antigen (LANA, ORF73) and vFLIP (F7), lytic genes (ORF50, ORF6, ORF59, F10), and an ORF unique to FcaGHV1, F20. In situ hybridization of FIV-associated DLBCLs (*n* = 9), post-transplant lymphomas (*n* = 6) and high-grade B and T-cell intestinal lymphomas (*n* = 8) identified a single case in which FcaGHV1 nucleic acid was detectable. These results demonstrate that FcaGHV1 transcripts can be detected in some FIV-associated lymphomas, but at low copy number, precluding assessment of a potential role for FcaGHV1 in lymphomagenesis. Future investigation of the FcaGHV1 transcriptome in clinical samples might employ viral enrichment and greater sequencing depth to enhance the retrieval of viral reads. Our results suggest prioritization of a subset of intestinal T-cell tumors, large granular lymphocyte lymphoma, for study.

Keywords: gammaherpesvirus; immunodeficiency; virus; domestic cat; felid; lymphomagenesis; oncogenic; transcriptome; lymphoma; cancer; B-cell; T-cell

---

Felis catus gammaherpesvirus 1 (FcaGHV1; proposed species *Felid gammaherpesvirus 1*) was first reported in domestic cats in 2014 [1]. The targeted search that discovered FcaGHV1 was predicated...
on the hypothesis that a gammaherpesvirus would be causal in feline immunodeficiency virus (FIV)-associated lymphoma, just as the Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV), are causal in 30–95% of HIV-associated lymphomas in humans [2,3]. Understanding the pathogenic potential of FcaGHV1 in cats is relevant to an expanding companion animal health market and may provide insights into human disease.

Herpesviruses alternate between lytic and latent replication cycles. During viral latency, the genome is maintained as an episome and a limited repertoire of genes is transcribed. Latency-associated transcripts collectively confer a survival advantage to maintain a viral reservoir through diverse mechanisms that promote cell growth, inhibit apoptosis and downregulate immunological targets [4]. These same genes promote cell transformation and gammaherpesvirus-associated cancers, including lymphoma. Oncogenesis occurs in a minority of gammaherpesvirus infections, often many years after the primary infection. Predisposing factors, such as immunodeficiency, are identified in some, but not all cases [5]. Although rare, gammaherpesvirus-associated cancers are frequently fatal. A full understanding of the mechanisms by which specific gammaherpesviruses transform cells is evolving, but the presence of transcriptionally active virus within cancer cells is a prerequisite to establish a direct causal relationship. In addition to established repertoires of latency-associated transcripts, an increasing number of lytic genes are implicated in tumorigenesis [6–9]. The role of gammaherpesviruses in oncogenesis can be informed from the spectrum of genes transcribed in cancer cells.

FcaGHV1 infection has been reported in cats from Australia, USA, UK, central Europe, Japan, Singapore and Brazil, with 9.6% to 23.6% testing positive for FcaGHV1 on whole blood quantitative real-time PCR (qPCR) [1,10–14]. One study showed that anti-FcaGHV1 antibodies identified persistent infection in 35% of cats, and the true infection prevalence may be higher [15]. So, while FcaGHV1 infection is common, any disease that it might cause is expected to be rare. Defining the pathogenicity of FcaGHV1 will rely on accumulating evidence from multiple lines of investigation.

We investigated the transcriptome of FIV-associated lymphomas with complimentary techniques, deep sequencing and reverse transcriptase (RT)-PCR, to identify FcaGHV1 transcription. In situ hybridization (ISH) was used to identify the cellular location of FcaGHV1 nucleic acid in FIV-associated lymphomas, post-transplant lymphomas and high-grade B and T-cell gastrointestinal lymphomas.

Transcriptome analysis was performed on large cell, high-grade B-cell lymphomas consistent with diffuse large B cell lymphoma (DLBCL), arising in cats infected with FIV [16]. The antemortem diagnosis of FIV was based on a positive serology result in a cat that had not been vaccinated against FIV [17]. Necropsy samples were stored at −80 °C for transcriptome analysis. Sample collection was approved by the University of Sydney Animal Ethics Committee N00/7-2013/3/6029 and 2014/626. Cases were included if they tested positive for FcaGHV1 DNA in whole blood by qPCR or tumour tissue by conventional PCR (cPCR) [1,18] (n = 10). Cases were excluded if they tested seropositive for the directly oncogenic gammaretrovirus feline leukemia virus (FeLV) [19]. FIV infection status was confirmed by PCR of tumour-derived DNA for FIV gag, as described previously [18]. Total RNA was extracted from frozen tumour, as described previously [20]. In the first round of NGS, libraries were prepared for cases 1, 2 and 8 using a TruSeq RNA library preparation kit (Illumina, San Diego, CA, USA). Cytoplasmic ribosomal RNA was depleted using a Ribo-Zero Gold rRNA removal kit (epidemiology) (Illumina). The 75 bp paired-end libraries were then run on an Illumina NextSeq platform (San Diego, CA, USA). Library preparation for a second round of RNA sequencing was performed for samples 1 to 10 (Table 1) using identical preparation except that ribosomal RNA was removed using a Ribo-Zero Gold rRNA removal kit (epidemiology) (Illumina). RNA sequencing of 100 bp paired-end libraries was performed on an Illumina HiSeq 2500 platform. To estimate the abundance of FIV and FcaGHV1, the reads from each library were mapped to the corresponding genomes using Bowtie2 software [21]. The mapping results were subsequently visualized and manually examined using the Interactive Genomic Viewer (http://software.broadinstitute.org). To confirm the mapping results, we also performed blastn [22] and diamond blast [23] analyses of reads, against the comprehensive non-redundant nucleotide (nt)
and protein (nr) databases, respectively. The reads identified as FcaGHV1 transcripts were consistent with those discovered by the mapping approach. For comparison, the reads were also mapped to beta-glucuronidase (GUSB) which is stably expressed in cats [24]. Viral reads mapping to FcaGHV1 lytic gene homologs ORF50, ORF6, ORF59, F10 were recovered. ORF50 triggers reactivation from latency and inhibits apoptosis [25]. F10, a KSHV K3 homolog, and down regulates MHC-I, whereas ORF59 and ORF6 encode a polymerase and a DNA binding protein, respectively. Two reads mapped to an ORF unique to FcaGHV1, F20, of unknown function [26].

Table 1. Summary of transcriptome analyses of feline immunodeficiency virus associated lymphoma from FcaGHV1 infected cats.

| Cases | NextSeq FcaGHV1 Reads | HiSeq Number of Reads | RT-PCR |
|-------|------------------------|-----------------------|--------|
|       |                        | Total | GUSB | FIV | FcaGHV1 | FcaGHV1 | FcaGHV1 | FcaGHV1 |
|       |                        |       |      |     |         | ORF50   | ORF59   | ORF6    |
| 1     | Neg                    | 294,779,800 | 4149 | 1023 | 0        | Neg      | Neg      | Neg      |
| 2     | 4 (ORF 50)            | 338,384,008 | 8070 | 2959 | 0        | POS      | POS      | POS      |
| 3     | -                      | 288,176,064 | 4152 | 48,270 | 0        | Neg      | Neg      | Neg      |
| 4     | -                      | 317,655,184 | 6526 | 32 | 0    | POS      | Neg      | POS      |
| 5     | -                      | 300,408,704 | 1608 | 4090 | 0        | Neg      | Neg      | POS      |
| 6     | -                      | 321,297,408 | 12,866 | 1636 | 2        | Neg      | Neg      | POS      |
| 7     | -                      | 337,067,856 | 21,636 | 100    | 0        | Neg      | Neg      | Neg      |
| 8     | Neg                    | 326,445,528 | 5103 | 2207 | 0        | POS      | Neg      | POS      |
| 9     | -                      | 313,060,728 | 1410 | 141 | 2 (F10) | Neg      | Neg      | Neg      |
| 10    | -                      | 239,825,576 | 1973 | 11 | 0        | Neg      | Neg      | Neg      |

Table 2. Oligonucleotides used to detect Felis catus gammaherpesvirus 1 transcripts in feline immunodeficiency virus associated lymphoma by RT-PCR.

| Oligonucleotide | Sequence | Size (bp) | Tm (°C) |
|-----------------|----------|-----------|---------|
| ORF50-F1        | 5′-CCCCAGGGGTTCCTTGTGGAA-3′ | 301 | 57 |
| ORF50-R1        | 5′-GGGCTTGACTCAACGACCG-3′ | 57 |
| ORF73-F2        | 5′-CAGCGGCGATGTTTGACGAC-3′ | 110 | 57 |
| ORF73-R2        | 5′-CCTACATGCGCTACTACA-3′ | 57 |
| F7-F            | 5′-ACTCTGTGTGTCTGGGAATGTTGAC-3′ | 153 | 56 |
| F7-R            | 5′-TGGCTTGCTGTATAGGCGCCAGC-3′ | 56 |
For ISH, formalin-fixed paraffin-embedded (FFPE) tissues from 9 of the FIV-associated lymphomas were investigated. In addition, archived diagnostic samples from post-renal transplant large B-cell lymphomas ($n = 6$) and high-grade B- and T-cell gastrointestinal lymphomas ($n = 8$) were retrieved. The causal role for gammaherpesviruses in lymphomas arising in human transplant recipients provided the rationale for investigating feline post-transplant lymphomas [28]. High grade gastrointestinal lymphomas were included because the global control of FeLV has seen these tumors become a dominant subtype and their cause is unknown [29,30]. FFPE tumour-derived DNA from post-transplant and gastrointestinal tumours was tested for FcaGHV1 by cPCR prior to ISH, as described previously [18]. An anti-sense ISH probe for FcaGHV1 ORF50 was custom-designed (Advanced Cell Diagnostics, Newark, CA, USA). This probe can detect both DNA and RNA, where the target is a double-stranded DNA virus, such as a herpesvirus. Four-micron tissue sections were prepared on charged glass slides (Superfrost Plus, Thermoscientific, Waltham, MA, USA). Sample preparation and pretreatment for the RNAscope 2.5 Assay were carried out according to the manufacturer’s instructions (Advanced Cell Diagnostics, Newark, CA, USA). Hybridized probe was identified with RNAscope®2.5 HD Detection Reagent-Red. Samples were tested with an FcaGHV1 ORF50 probe, and a probe for bacterial gene DapB served as a negative control.

Transcriptomic analyses detected a limited repertoire of FcaGHV1 transcripts (100% match) in 5 of 10 FIV-associated lymphomas (Table 1). FcaGHV1 transcripts included homologs of KSHV latency-associated transcripts LANA and vFLIP, which induce B-cell lymphomas in mice [31,32]. LANA, KSHVs major latency protein, contributes to the maintenance of episomal DNA in proliferating cells, by tethering the episome to the host genome. The mechanisms by which LANA promotes KSHV-associated lymphomagenesis include the inhibition of tumor suppressor genes p53 and Rb, and stabilization of protooncogene-encoded MYC [27]. vFLIP has anti-apoptotic effects mediated by preventing the activation of the protease, caspase 8 [27]. Although only 2 to 4 reads per FcaGHV1 transcript were detected, we believe that the transcripts can be considered genuine as they were identified using multiple approaches. In addition, we initially discovered a novel domestic cat hepadnavirus from 8 transcripts in case 6, which was later confirmed by PCR in a larger number of animals [20].

Metatranscriptomics of clinical samples can reveal the pattern of viral gene expression within cancer cells, without bias introduced by viral enrichment. Nonetheless, the direct investigation of clinical samples presents several challenges. Firstly, host non-rRNA reads are expected to dwarf those of a latent virus. The very low abundance of transcripts retrieved, suggests that the sensitivity of these methods is close to the lower limit of detection for FcaGHV1 transcripts in clinical specimens. Secondly, tumors are heterogeneous containing inflammation and necrosis alongside cancer cells, and cells undergoing lytic as well as latent virus replication. This can contribute to inconsistency in results as a consequence of sampling different regions of the same tumor. Future investigations of the FcaGHV1 transcription profile in clinical specimens, invoking deeper sequencing, library baiting, and absolute quantitation are expected to yield valuable information.

One post-transplant lymphoma and one gastrointestinal lymphoma tested positive for FcaGHV1 by cPCR. From 23 tumors tested by ISH, a single gastrointestinal lymphoma yielded a positive result. This tumor, a high-grade, T-cell lymphoma, subtyped as a large granular lymphocyte lymphoma, was the sample that tested positive for FcaGHV1 by cPCR. A positive intranuclear signal was identified in >90% of neoplastic lymphocytes. This result has been repeatable in two laboratories (PP and JB) (Figure 1). An identical pattern of staining was obtained when this tumor was tested by ISH for FcaGHV1 ORF73 and with a combined F7, F10, F20 probe. In contrast, the other 22 lymphomas were consistently negative for FcaGHV1 on ISH, and the unrelated control probe gave a negative result in all 23 samples with ISH. In the single ISH positive tumor, the consistent intranuclear signal and the absence of a cytoplasmic signal with any FcaGHV1 ISH probe, supports that episomal FcaGHV1 DNA is maintained in the majority of neoplastic lymphocytes in this intestinal T-cell, large granular lymphocyte lymphoma. Further studies are required to understand whether the continued presence of
the virus is required to maintain tumor phenotype, as it is with other GHV-associated cancers [33]. Of note here, the published FcaGHV1 genome sequence was obtained from a lymph node, selected for its high FcaCaGHV1 load of 48 FcaGHV1 genomes per cell, from a case of high-grade, T-cell intestinal lymphoma [26].

![Image](https://example.com/image.jpg)

**Figure 1.** Detection of FcaGHV1 by in situ hybridization in an intestinal large, granular lymphocyte lymphoma. In situ hybridization for FcaGHV1 ORF 50. Bars 50 micrometers. (a) A strong intranuclear signal (red) labels >90% of infiltrating neoplastic lymphocytes that are densely packed within intestinal villi. Counterstain, hematoxylin; (b) high power image to show nuclear staining of neoplastic lymphocytes; (c) no staining with negative control probe DapB (d) hematoxylin and eosin.

In summary, FcaGHV1 transcripts can be detected in some FIV-associated lymphomas, but at low copy number which precludes assessment of a potential role for FcaGHV1 in lymphomagenesis. Our results identify a subset of intestinal T-cell tumors, large granular lymphocyte lymphoma that can be targeted in future investigations of the pathogenic potential of FcaGHV1.

**Author Contributions:** M.A., M.S., P.A.P., V.R.B., E.C.H. and J.A.B. designed and conducted the study and wrote the manuscript; R.M.T. contributed to study design and reviewed the manuscript; A.C.D., T.P. and S.L.D. contributed essential data and reviewed the manuscript.

**Funding:** This research was funded by the Winn Feline Foundation (W17-011), the Morris Animal Foundation (D15FE-001) and the Australian Companion Animal Health Foundation (004/2018). ECH is funded by an ARC Australian Laureate Fellowship (FL170100022).

**Acknowledgments:** We thank Sydney Informatics Core Research Facility and the University of Sydney HPC service at The University of Sydney for providing bioinformatics resources that contributed to the results. ECH is funded by an ARC Australian Laureate Fellowship (FL170100022).

**Conflicts of Interest:** The authors declare no conflicts of interest.

**References**

1. Troyer, R.M.; Beatty, J.A.; Stutzman-Rodriguez, K.R.; Carver, S.; Lozano, C.C.; Lee, J.S.; Lappin, M.R.; Riley, S.P.D.; Serieys, L.E.K.; Logan, K.A.; et al. Novel Gammaherpesviruses in North American Domestic Cats, Bobcats, and Pumas: Identification, Prevalence, and Risk Factors. *J. Virol.* 2014, 88, 3914–3924. [CrossRef] [PubMed]
2. Beatty, J.A.; Troyer, R.M.; Brewster, C.; Rovnak, R.; Barrs, V.R.; Quackenbush, S.L.; VandeWoude, S. Feline immunodeficiency virus (FIV)-associated lymphoma. Is a gammaherpesvirus involved? In Proceedings of the 2nd International Society for Companion Animal Infectious Diseases Symposium, San Francisco, CA, USA, 14-17 November 2012; p. 27.

3. Pinzone, M.R.; Berretta, M.; Cacopardo, B.; Nunnari, G. Epstein-Barr Virus- and Kaposi Sarcoma-Associated Herpesvirus-Related Malignancies in the Setting of Human Immunodeficiency Virus Infection. Semin. Oncol. 2015, 42, 258–271. [CrossRef] [PubMed]

4. Ackermann, M. Pathogenesis of gammaherpesvirus infections. Vet. Microbiol. 2016, 113, 211–222. [CrossRef] [PubMed]

5. Pierangeli, A.; Antonelli, G.; Gentile, G. Immunodeficiency-associated viral oncogenesis. Clin. Microbiol. Infect. 2015, 21, 975–983. [CrossRef] [PubMed]

6. Tierney, R.J.; Shannon-Lowe, C.D.; Fitzsimmons, L.; Bell, A.I.; Rowe, M. Unexpected patterns of Epstein-Barr virus transcription revealed by a High throughput PCR array for absolute quantification of viral mRNA. Virology 2015, 474, 117–130. [CrossRef] [PubMed]

7. Grundhoff, A.; Ganem, D. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J. Clin. Invest. 2004, 113, 124–136. [CrossRef] [PubMed]

8. Hoshino, Y.; Katano, H.; Zou, P.; Hohman, P.; Marques, A.; Tying, S.K.; Follmann, D.; Cohen, J.I. Long-Term Administration of Valacyclovir Reduces the Number of Epstein-Barr Virus (EBV)-Infected B Cells but Not the Number of EBV DNA Copies per B Cell in Healthy Volunteers. J. Virol. 2009, 83, 11857–11861. [CrossRef] [PubMed]

9. Borozan, I.; Zapatka, M.; Frappier, L.; Ferretti, V. Analysis of Epstein-Barr Virus Genomes and Expression Profiles in Gastric Adenocarcinoma (vol 92, e01239-17, 2018). J. Virol. 2018, 92. [CrossRef] [PubMed]

10. Ertl, R.; Korb, M.; Langbein-Detsch, I.; Klein, D. Prevalence and risk factors of gammaherpesvirus infection in domestic cats in Central Europe. Virol. J. 2015, 12, 146. [CrossRef] [PubMed]

11. Kurissio, J.K.; Rodrigues, M.V.; Taniwaki, S.A.; Zanutto, M.D.; Filoni, C.; Galdino, M.V.; Araujo, J.P. Felis catus gammaherpesvirus 1 (FcaGHV1) and coinfections with feline viral pathogens in domestic cats in Brazil. Cienc. Rural 2018, 48. [CrossRef]

12. Stutzman-Rodriguez, K.; Rovnak, J.; VandeWoude, S.; Troyer, R.M. Domestic cats seropositive for Felis catus gammaherpesvirus 1 are often qPCR negative. Virology 2016, 498, 23–30. [CrossRef] [PubMed]

13. Liem, B.; Dhand, N.; Pepper, A.; Barrs, V.; Beatty, J. Viral causes of feline lymphoma: Retroviruses and beyond. Vet. J. 2014, 201, 174–180. [CrossRef] [PubMed]

14. Aghazadeh, M.; Shi, M.; Barrs, V.; McLuckie, A.; Lindsay, S.; Jameson, B.; Hampson, B.; Holmes, E.; Beatty, J. A Novel Hepadnavirus Identified in an Immunocompromised Domestic Cat in Australia. Viruses 2018, 10, 269. [CrossRef] [PubMed]

15. Langmead, B.; Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 2012, 9, 357–359. [CrossRef] [PubMed]
22. Altschul, S.F.; Gish, W.; Miller, W.; Myers, E.W.; Lipman, D.J. Basic Local Alignment Search Tool. J. Mol. Biol. 1990, 215, 403–410. [CrossRef]
23. Buchfink, B.; Xie, C.; Huson, D.H. Fast and sensitive protein alignment using DIAMOND. Nat. Methods 2015, 12, 59–60. [CrossRef] [PubMed]
24. Penning, L.C.; Vrieling, H.E.; Brinkhof, B.; Riemers, F.M.; Rothuizen, J.; Ruttenman, G.R.; Hazewinkel, H.A.W. A validation of 10 feline reference genes for gene expression measurements in snap-frozen tissues. Vet. Immunol. Immunopathol. 2007, 120, 212–222. [CrossRef] [PubMed]
25. Damania, B.; Jeong, J.H.; Bowser, B.S.; DeWire, S.M.; Staudt, M.R.; Dittmer, D.P. Comparison of the Rta/Orf50 transactivator proteins of gamma-2-herpesviruses. J. Virol. 2004, 78, 5491–5499. [CrossRef] [PubMed]
26. Troyer, R.M.; Lee, J.S.; Vuyisich, M.; Chain, P.; Lo, C.-C.; Krommiller, B.; Bracha, S.; Avery, A.C.; VandeWoude, S. First Complete Genome Sequence of Felis catus Gammaherpesvirus 1. Genome Announc. 2015, 3. [CrossRef] [PubMed]
27. Giffin, L.; Damania, B. KSHV: Pathways to Tumorigenesis and Persistent Infection. In Advances in Virus Research; Maramorosch, K., Murphy, F.A., Eds.; Elsevier: London, UK, 2014; Volume 88, pp. 111–159.
28. Chapman, J.R.; Webster, A.C.; Wong, G. Cancer in the Transplant Recipient. Cold Spring Harb. Perspect. Med. 2013, 3. [CrossRef] [PubMed]
29. Louwerens, M.; London, C.A.; Pedersen, N.C.; Lyons, L.A. Feline lymphoma in the post-feline leukemia virus era. J. Vet. Intern. Med. 2005, 19, 329–335. [PubMed]
30. Meichner, K.; Kruse, B.D.; Hirschberger, J.; Hartmann, K. Changes in prevalence of progressive feline leukaemia virus infection in cats with lymphoma in Germany. Vet. Rec. 2012, 171, 348. [CrossRef] [PubMed]
31. Ballon, G.; Chen, K.; Perez, R.; Tam, W.; Cesman, E. Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorogenesis in mice. J. Clin. Investig. 2011, 121, 1141–1153. [CrossRef] [PubMed]
32. Fakhari, F.D.; Jeong, J.H.; Kanan, Y.; Dittmer, D.P. The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J. Clin. Investig. 2006, 116, 735–742. [CrossRef] [PubMed]
33. Mariggio, G.; Koch, S.; Schulz, T.F. Kaposi sarcoma herpesvirus pathogenesis. Philos. Trans. R. Soc. B Biol. Sci. 2017, 372. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).